COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 182 participants.
Also called NCT05250596
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 182 participants
- Sponsor
- Azienda USL Toscana Centro
- Registry
-
NCT05250596 -
2021-000637-13
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT05250596. Randomized; no masking; primary purpose treatment. Start 2022-02-24 (actual); primary completion 2024-02-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)
- Acronym
- COLOR-ACS
- Condition
- Non ST Segment Elevation Acute Coronary Syndrome
- Intervention (Drug)
- Colchicine
- Intervention (Drug)
- Atorvastatin
- Lead sponsor
- Azienda USL Toscana Centro
Record details
- Record id
cardio:ct-nct05250596- Content hash
3dd405cb988cbba9b24b29610774315c920450ec86d82dd83f660a928e19e6d0